Psychiatric comorbidity, psychological distress, and quality of life in gamma-hydroxybutyrate-dependent patients

References

• Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow G. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psych 1997; 54(1):71–80.
   PubMed Web of Science ®Google Scholar
• Pereiro C, Pino C, Florez G, Arrojo M, Becona E. Psychiatric comorbidity in patients from the addictive disorders assistance units of Galicia: the COPSIAD study. PLoS One 2013; 8(6):e66451.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, O'Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psych 2013; 170(1):23–30.
   PubMed Web of Science ®Google Scholar
• Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence. Brit J Psych 2000; 176:285–9.
   Web of Science ®Google Scholar
• Brady KT, Sinha R. Co-occurring mental and substance use disorders:the neurobiological effects of chronic stress. Am J Psych 2005; 162:1483–93.
   PubMed Web of Science ®Google Scholar
• Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psych 1985; 142:1259–64.
   PubMed Web of Science ®Google Scholar
• Swendsen J, Conway KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction 2010; 105(6):1117–28.
   PubMed Web of Science ®Google Scholar
• Breslau N, Novak SP, Kessler RC. Psychiatric disorders and stages of smoking. Biol Psych 2004; 55:69–76.
   PubMed Web of Science ®Google Scholar
• Sepehrmanesh Z, Ahmadvand A, Moraveji A. Comorbidity and pattern of substance use in hospitalized psychiatric patients. Iran Red Crescent Med J. 2014; 16(8):e19282.
   PubMed Web of Science ®Google Scholar
• Volkow N, Fowler, JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000; 10:318–25.
   PubMed Web of Science ®Google Scholar
• Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psych 2002; 51(10):775–87.
   PubMed Web of Science ®Google Scholar
• Piazza PV, Le Moal M. The role of stress in drug self-administration. Trends Pharmacol Sci 1998; 19:67–74.
   PubMed Web of Science ®Google Scholar
• Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacol (Berl) 2001; 158(4):343–59.
   PubMed Web of Science ®Google Scholar
• Bartels SJ, Drake RE, McHugo GJ. Alcohol abuse, depression, and suicidal behavior in schizophrenia. Am J Psych 1992; 149(3):394–5.
   PubMed Web of Science ®Google Scholar
• Bizzarri J, Rucci P, Vallotta A. Dual diagnosis and quality of life in patients in treatment for opioid dependence. Subst Use Misuse 2005; 40(12):1765–76.
   PubMed Web of Science ®Google Scholar
• Fassino S, Daga GA, Delsedime N, Rogna LSB. Quality of life and personality disorders in heroin abusers. Drug Alcohol Depend 2004; 76(1):73–80.
   PubMed Web of Science ®Google Scholar
• González-Saiz F, Rojas OL, Castillo II. Measuring the impact of psychoactive substance on health-related quality of life: an update. Current Drug Abuse Rev 2009; 2:5–10.
   PubMedGoogle Scholar
• Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 2002; 28:643–52.
   PubMed Web of Science ®Google Scholar
• Rush B, Kroegl, CJ. Prevalence and profile of people with co-occurring mental and substance use disorders within a comprehensive mental health system. Can J Psych 2008; 53(12):810–21.
   Web of Science ®Google Scholar
• Stein LA, Lebeau R, Clair M, et al. A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use. Am J Addict 2011; 20(1):30–9.
   PubMed Web of Science ®Google Scholar
• EMCDDA. Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 2002.
   Google Scholar
• Durgahee S, Allen, G, Williams, H. The “G” men: a profile of GBL/GHB users in an area of high drug-related mortality. Ir. J. Psychol. Med 2014; 31(4):275–80.
   Google Scholar
• Götz W. European drug report: trends and developments. Luxembourg: European Union: The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2013.
   Google Scholar
• Johnson MW, Griffiths RR. Comparative abuse liability of GHB and ethanol in humans. Exp Clin Psychopharmacol 2013; 21(2):112–23.
   PubMed Web of Science ®Google Scholar
• Matgorzata F. GABAB receptors in drug addiction. Pharmacol Reports 2008; 60:755–70.
   PubMed Web of Science ®Google Scholar
• Bosch O, Quednow BB, Seifritz E, Wetter TC. Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol 2012; 26(5):618–28.
   PubMed Web of Science ®Google Scholar
• Maremmani AGI, Bacciardi S, Rovai L, Rugani F, Dell'Osso L, Maremmani I. Sodium oxybate as off-label treatment for anxiety disorder: successful outcome in a low-energy anxious resistant patient. Addictive Disorders & Their Treat 2015; 14(4): 198–202.
   Web of Science ®Google Scholar
• Wisselink D, Mol A. GHB treatment demand in the Netherlands: major developments in treatment demand issues within the addiction care for GHB addiction 2007–2012. Houten, Netherlands: Landelijk Alcohol en Drugs Informatie Systeem (LADIS), 2013.
   Google Scholar
• Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011; 29(3):319–32.
   PubMed Web of Science ®Google Scholar
• van Noorden MS, Kamal R, de Jong CA, Vergouwen AC, Zitman F. Gamma-hydroxybutyric acid (GHB) dependence and the GHB withdrawal syndrome: diagnosis and treatment. Nederlands Tijdschrift Voor Geneeskunde 2010; 154 (A 1286).
   PubMedGoogle Scholar
• Boonstra M. Ontwenning van ghb: een voorbeeldpraktijk (Detoxification of GHB: a model for clinical practice). Verslaving 2011; 7:3–15.
   Google Scholar
• de Jong C, Kamal R, Dijkstra BA, de Haan HA. Gamma-hydroxybutyrate detoxification by titration and tapering. Eur Addict Res 2012; 18(1):40–5.
   PubMed Web of Science ®Google Scholar
• Kamal R, Dijkstra BAG, van Iwaarden JA, van Noorden MS, de Jong CAJ. Practice-based recommendations for the detoxification of patients with GHB abuse disorders (protocol in Dutch). The Netherlands: Resultaten Scoren, Amersfoort, 2013.
   Google Scholar
• Corkery J, Loi B, Claridge H, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev 2015; 53:52–78.
   PubMed Web of Science ®Google Scholar
• van Vliet IM, de Beurs E. The MINI-International Neuropsychiatric Interview. A brief structured diagnostic psychiatric interview for DSM-IV en ICD-10 psychiatric disorders. Tijdschr Psych 2007; 49(6):393–7.
   PubMedGoogle Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD10. J Clin Psych 1998; 59(Suppl 20):22–33.
   Google Scholar
• Lovibond SH, Lovibond PF. Manual for the depression anxiety & stress scales 2nd ed., In: Foundation P, ed. Sydney, Australia: Psychology Foundation of Australia, 1995.
   Google Scholar
• Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behavioral Research Ther 1997; 35(1):79–89.
   PubMed Web of Science ®Google Scholar
• Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983; 13(3):595–605.
   PubMed Web of Science ®Google Scholar
• Derogatis LR. The brief symptom inventory (BSI). Administration, scoring and procedures manual, 3rd ed., New York, NY: National Computer Systems, 1993.
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11):1095–108.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Schippers GM, Broekman TG, Buchholz A, Koeter MW, van den Brink W. Measurements in the Addictions for Triage and Evaluation (MATE): an instrument based on the World Health Organization family of international classifications. Addiction 2010; 105(5):862–71.
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990; 264:2511–8.
   PubMed Web of Science ®Google Scholar
• Wong C, Gibson K, Snead O. From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends Pharmacol Sci 2004; 25(1):29–34.
   PubMed Web of Science ®Google Scholar
• Dijkstra B, De Weert-van Oene GH, Verbrugge CAG, De Jong C. End report GHB detoxification with pharmaceutical GHB monitor, in the Netherlands addiction care. Nijmegen, the Netherlands: Nijmegen Institute for Scientist-Practitioners in Addiction 2013.
   Google Scholar
• König HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psych 2007; 22(3):177–87.
   Web of Science ®Google Scholar
• Carpentier PJ, Krabbe PF, van Gogh MT, Knapen LJ, Buitelaar JK, de Jong CA. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict 2009; 18(6):470–80.
   PubMed Web of Science ®Google Scholar
• Caputo F, Francini S, Brambilla R, et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. Eur Neuropsychopharmacol 2011; 21(6):450–6.
   PubMed Web of Science ®Google Scholar
• Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend 2001; 64(2):233–41.
   PubMed Web of Science ®Google Scholar